Market: NASD |
Currency: USD
Address: 322 11th Avenue SW
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
📈 Oncolytics Biotech Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$4.47
-
Upside/Downside from Analyst Target:
329.91%
-
Broker Call:
10
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
0-10%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-12
-
EPS Estimate:
-0.07
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2018 |
- |
$0.105263 |
- |
2018-05-25 |
- |
Stock split |
|
Total Amount for 2018: $0.105263 |
📅 Earnings & EPS History for Oncolytics Biotech Inc.
| Date | Reported EPS |
|---|
| 2025-11-12 (estimated upcoming) | - |
| 2025-08-08 | -0.07 |
| 2025-05-14 | -0.08 |
| 2025-03-07 | -0.1 |
| 2024-11-12 | -0.12 |
| 2024-08-01 | -0.1 |
| 2024-05-09 | -0.09 |
| 2024-03-07 | -0.11 |
| 2023-11-03 | -0.13 |
| 2023-08-14 | -0.11 |
| 2023-05-05 | -0.1 |
| 2023-03-03 | -0.15 |
| 2022-11-07 | -0.08 |
| 2022-08-11 | -0.09 |
| 2022-05-05 | -0.12 |
| 2022-03-03 | -0.14 |
| 2021-11-05 | -0.09 |
| 2021-08-06 | -0.13 |
| 2021-05-07 | -0.13 |
| 2021-03-05 | -0.21 |
| 2020-11-11 | -0.16 |
| 2020-08-04 | -0.16 |
| 2020-05-08 | -0.1 |
| 2020-03-05 | -0.26 |
| 2019-11-12 | -0.16 |
📰 Related News & Research
No related articles found for "oncolytics biotech".
